✔ 100% Authentic Product
👁️ Currently Viewing 448
Navigo 40 Infusion | 40mg Vial
Nivolumab is a human IgG4 monoclonal antibody that targets the PD-1 receptor on T-cells, disrupting its interaction with PD-L1 and PD-L2. This releases the immune inhibition mediated by the PD-1 pathway, enabling T-cells to recognize and destroy cancer cells. When combined with ipilimumab (a CTLA-4 inhibitor), it enhances T-cell activation, promoting a more potent anti-tumor response.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Cash on Delivery - All over Bangladesh
Regular Delivery - 12-24 Hours, Dhaka City*- Regular Delivery - 24-48 Hours, All Over Bangladesh*
ফ্রি ডেলিভারি! - ১৪৯৯ টাকা+ অর্ডারে ঢাকা
শহরে ।
✅ Description:
Navigo 40 (Nivolumab) is a PD-1 immune checkpoint inhibitor indicated for the treatment of various cancers, including:
- Non-small cell lung cancer (NSCLC)
- Renal cell carcinoma (RCC)
- Melanoma
- Classical Hodgkin lymphoma (cHL)
- Liver cancer (Hepatocellular carcinoma)
- Head and neck squamous cell carcinoma (SCCHN)
- Urothelial carcinoma
- Esophageal and gastric cancers
- Colorectal cancer with MSI-H or dMMR
- Malignant pleural mesothelioma
✔️ Common Side Effects
- Fatigue, headache, rash, diarrhea, nausea, cough
- Musculoskeletal pain, back pain, pruritus, dyspnea, URTI
- Decreased appetite, abdominal pain, constipation, fever
✔️ Pregnancy & Lactation
- May harm the fetus; advise effective contraception during treatment and for 5 months post-therapy.
- Unknown if nivolumab is excreted in breast milk; breastfeeding decisions should consider the potential risks and benefits.
✔️ Dosage & Administration
Nivolumab is administered via intravenous infusion. The dosage and schedule vary by indication and may be used alone or in combination with ipilimumab, chemotherapy, or targeted therapy. Common regimens include:
- Monotherapy: 240 mg every 2 weeks or 480 mg every 4 weeks
- With ipilimumab: Dose varies by cancer type and patient body weight
- With chemotherapy or cabozantinib: Follow the specific regimen as per the indication
Infusions are given over 30 minutes using a sterile, low protein-binding filter.
Preparation
Dilute with 0.9% Sodium Chloride or 5% Dextrose to a final concentration of 1–10 mg/mL. Do not exceed 160 mL total infusion volume (or 4 mL/kg in patients under 40 kg). Mix gently—do not shake. Administer within 8 hours at room temperature or store up to 7 days at 2–8°C protected from light.
- Pediatric: Not established in patients under 12 years (mCRC) or under 18 for other uses.
- Geriatric: No significant differences in safety or efficacy compared to younger patients.
✔️ Precautions & Warnings
- Monitor for immune-related adverse events affecting the lungs, liver, endocrine organs, skin, and kidneys.
- Regularly assess liver function, renal function, and thyroid hormones.
- Interrupt or discontinue treatment depending on the severity of adverse reactions.
- Watch for infusion reactions; manage accordingly.
- Increased risk of complications post-allogeneic HSCT.
- Contraindicated with thalidomide analogs in multiple myeloma outside clinical trials.
✔️ Storage
Keep refrigerated at 2°C to 8°C. Do not freeze. Protect from light and keep out of children's reach.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.
